# Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

> **NCT04383938** · PHASE1,PHASE2 · COMPLETED · sponsor: **Aprea Therapeutics** · enrollment: 40 (actual)

## Conditions studied

- Bladder Cancer
- Gastric Cancer
- Non Small Cell Lung Cancer
- NSCLC
- Urothelial Carcinoma
- Advanced Solid Tumor

## Interventions

- **DRUG:** APR-246 (eprenetapopt) + Pembrolizumab

## Key facts

- **NCT ID:** NCT04383938
- **Lead sponsor:** Aprea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-25
- **Primary completion:** 2022-04-30
- **Final completion:** 2022-04-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04383938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04383938, "Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT04383938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*